Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma

Background: The Gustave Roussy Immune Score (GRIm-Score) was initially reported to select patients for immunotherapy.Therefore, the purpose of the current retrospective study was to determine whether GRIm-Score, a novel nutritional and inflammatory-based prognostic score, is a useful prognostic marker in patients with esophageal squamous cell carcinoma (ESCC) undergoing surgical resection.Methods: A retrospective single institutional study including 372 ESCC patients undergoing surgical resection was performed.The GRIm-Score was simply calculated by lactate dehydrogenase (LDH), neutrophil lymphocyte ratio (NLR) and albumin (ALB).The cancer-specific survival (CSS) was analyzed for the current study with Cox regression analyses with forward stepwise and Kaplan-Meier methods.Results: There were 284 (76.3%) men and 88 (23.7%) women with the mean age of 59.3 ± 8.0 years (range: 36-80 years).Patient with a high GRIm-Score had poor CSS (10.3% vs. 35.0%,P < 0.001).The GRIm-Score, in multivariate analyses, instead of NLR, LDH or ALB, was an independent prognostic factor for CSS (P = 0.004).Conclusion: The GRIm-Score was an independent prognostic marker in patients with ESCC undergoing surgical resection.Our study is also the first study to discuss the prognostic value of GRIm-Score in patients with resectable ESCC.